EP3515418
Notkun á c-Met hindrum til að meðhöndla krabbamein sem hýsa MET stökkbreytingar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.9.2017EP published:
14.4.2021EP application number:
17777211.8
EP translation filed:
5.7.2021Grant published:
15.8.2021EPO information:
European Patent Register
Max expiry date:
20.9.2037Expiry date:
20.9.2026Next due date:
30.9.2026
Title:
USE OF C-MET INHIBITORS TO TREAT CANCERS HARBOURING MET MUTATIONS
Timeline
Today
21.9.2017EP application
14.4.2021EP Publication
5.7.2021Translation submitted
15.8.2021Registration published
20.9.2026Expires
Owner
Name:
Astrazeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
FRIGAULT, Melanie MaeAddress:
Waltham, MA 02451, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201616116Date:
22.9.2016Country:
GB
Classification
Categories:
A61K 31/4985, A61K 31/00, A61P 35/00, G01N 33/48, C07K 16/28, A61K 31/5377, A61K 31/53, A61K 31/4745, A61K 31/47, A61K 31/4545, G01N 33/574, C12Q 1/6886
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 6.9.2021
Expires: 20.9.2022
Payer: Árnason Faktor ehf.
Number: 6
Paid: 16.8.2022
Expires: 20.9.2023
Payer: Árnason Faktor ehf.
Number: 7
Paid: 5.9.2023
Expires: 20.9.2024
Payer: Árnason Faktor ehf.
Number: 8
Paid: 7.8.2024
Expires: 20.9.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 15.9.2025
Expires: 20.9.2026
Payer: Árnason Faktor ehf.